{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:20:40Z","timestamp":1763662840319},"reference-count":11,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2007,12,6]],"date-time":"2007-12-06T00:00:00Z","timestamp":1196899200000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pacing Clinical Electrophis"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:p> <jats:bold>\n            <jats:italic>Background:<\/jats:italic>\n          <\/jats:bold>\n          <jats:italic>Dofetilide (D) is a highly selective blocker of the rapid component of the delayed rectifier potassium current and was approved for the treatment of atrial fibrillation (AF) based on a satisfactory safety\/efficacy profile from trials in patients with left ventricle (LV) dysfunction or heart failure. The dose\u2010dependant acute conversion rates (&lt;72 hours) were reported to be in the range of 6\u201330%. We hypothesized that the acute pharmacological conversion rate of D is higher than previously reported if used in a healthier cohort of patients with persistent AF.<\/jats:italic> <\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Methods and Results:<\/jats:italic>\n          <\/jats:bold>\n          <jats:italic>Eighty consecutive patients received D dosing per Cockroft\u2010Gault adjustment for creatinine clearance and QTc intervals. Patients were 61 \u00b1 10 years, 79% male, ejection fraction (EF) 53 \u00b1 13%, coronary artery disease 20%, and left atrial dimension 4.1 \u00b1 0.2 cms. The duration of the treated AF episode was a median of 19 days (range 10\u2013113 days). All patients received D while on telemetry for at least six dosing intervals. After 2.2 \u00b1 1.2 doses, 77% of patients converted to sinus rhythm (SR) and 23% did not and required direct current (DC) cardioversion. Acute pharmacological conversion rates were: 20% for D 125 mcg bid, 44% for 250 mcg bid, and 85% for 500 mcg bid. None of the patients had torsade de pointes and none had to stop D for intolerance. Failure to convert to SR on D alone was associated with larger left atrium (LA) diameter (P = 0.04), longer duration of AF (P = 0.02), and use of lower dosages of D (P = 0.04).<\/jats:italic> <\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Conclusions:<\/jats:italic>\n          <\/jats:bold>\n          <jats:italic>D had an unusually high pharmacological conversion rate, demonstrated an incremental dose response, and was well tolerated and safe, in a relatively healthy adult cohort with persistent AF. In addition to D dose, pharmaco\u2010conversion was predicted by LA size and AF duration. D is a desirable alternative for conversion of AF in a variety of clinical settings.<\/jats:italic> <\/jats:p>","DOI":"10.1111\/j.1540-8159.2007.00902.x","type":"journal-article","created":{"date-parts":[[2010,8,18]],"date-time":"2010-08-18T13:35:08Z","timestamp":1282138508000},"page":"1527-1530","source":"Crossref","is-referenced-by-count":14,"title":["Acute Conversion of Persistent Atrial Fibrillation During Dofetilide Initiation"],"prefix":"10.1111","volume":"30","author":[{"given":"DELIA","family":"COTIGA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AYSHA","family":"ARSHAD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EMAD","family":"AZIZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SANDEEP","family":"JOSHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JAYANTHI N.","family":"KONERU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JONATHAN S.","family":"STEINBERG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,12,6]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"313","article-title":"Safety of new anti\u2010arrhythmic drugs","volume":"98","author":"Touboul P","year":"2005","journal-title":"Arch Mal Coeur Vaiss"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.19.2385"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-004-0002-y"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi583"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/107424840501000307"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.21.2665"},{"key":"e_1_2_6_8_2","first-page":"1633","article-title":"Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) study","volume":"98","author":"Greenbaum RA CT","year":"1998","journal-title":"Circulation"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909163411201"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03402-4"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1540-8167.2003.90402.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041705"}],"container-title":["Pacing and Clinical Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1540-8159.2007.00902.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1540-8159.2007.00902.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T21:09:09Z","timestamp":1697144949000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1540-8159.2007.00902.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["10.1111\/j.1540-8159.2007.00902.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1540-8159.2007.00902.x","archive":["Portico"],"relation":{},"ISSN":["0147-8389","1540-8159"],"issn-type":[{"value":"0147-8389","type":"print"},{"value":"1540-8159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}